Head-To-Head Review: SAB Biotherapeutics (NASDAQ:SABS) vs. MiNK Therapeutics (NASDAQ:INKT)

SAB Biotherapeutics (NASDAQ:SABS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for SAB Biotherapeutics and MiNK Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0	1	1	0	2.50
MiNK Therapeutics	0	0	3	0	3.00

SAB Biotherapeutics currently has a consensus target price of $1.00, indicating a potential upside of 9.89%. MiNK Therapeutics has a consensus target price of $6.50, indicating a potential upside of 537.25%. Given MiNK Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than SAB Biotherapeutics.

Institutional and Insider Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are owned by institutional investors. 31.2% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 17.8% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

SAB Biotherapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.

Earnings and Valuation

This table compares SAB Biotherapeutics and MiNK Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$23.90 million	1.99	-$18.74 million	N/A	N/A
MiNK Therapeutics	N/A	N/A	-$27.99 million	($0.73)	-1.40

SAB Biotherapeutics has higher revenue and earnings than MiNK Therapeutics.

Profitability

This table compares SAB Biotherapeutics and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-664.68%	-108.59%	-63.27%
MiNK Therapeutics	N/A	-665.42%	-148.10%

Summary

SAB Biotherapeutics beats MiNK Therapeutics on 7 of the 11 factors compared between the two stocks.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.